Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

[1]  J. E. Bennett,et al.  Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 2014 .

[2]  S. Streatfield,et al.  Hybrid viral vectors for vaccine and antibody production in plants. , 2013, Current pharmaceutical design.

[3]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[4]  J. Wilschut,et al.  Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice , 2012, PloS one.

[5]  Qiang Chen,et al.  Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations , 2012, Plant Cell Reports.

[6]  D. Graham,et al.  Norovirus vaccine against experimental human Norwalk Virus illness. , 2011, The New England journal of medicine.

[7]  W. Beçak,et al.  Production of L1 protein from different types of HPV in Pichia pastoris using an integrative vector. , 2011, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[8]  V. Masenga,et al.  Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants , 2011, BMC biotechnology.

[9]  J. Sánchez-Vizcaíno,et al.  Characterization of Protection Afforded by a Bivalent Virus-Like Particle Vaccine against Bluetongue Virus Serotypes 1 and 4 in Sheep , 2011, PloS one.

[10]  D. Bernstein,et al.  Safety and immunogenicity of a candidate parvovirus B19 vaccine. , 2011, Vaccine.

[11]  R. Compans,et al.  Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. , 2011, The Journal of infectious diseases.

[12]  G. Glenn,et al.  H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric Form of Influenza Virus Hemagglutinin in Humans , 2011, Journal of Virology.

[13]  T. Tumpey,et al.  Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. , 2011, Vaccine.

[14]  G. Glenn,et al.  Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico , 2011, Vaccine.

[15]  V. Ward,et al.  Cross‐presentation of epitopes on virus‐like particles via the MHC I receptor recycling pathway , 2011, Immunology and cell biology.

[16]  M. Tanner,et al.  Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children , 2011, PloS one.

[17]  L. Lopalco,et al.  Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. , 2011, Vaccine.

[18]  Mengfeng Li,et al.  Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice , 2011, Virology Journal.

[19]  U. Rinas,et al.  Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the Hepatitis B surface antigen , 2011, Microbial cell factories.

[20]  M. Staufenbiel,et al.  The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects , 2011, The Journal of Neuroscience.

[21]  Jens Nielsen,et al.  Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae , 2011, Microbial cell factories.

[22]  P. Bonilauri,et al.  One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. , 2011, Veterinary microbiology.

[23]  D. Ho,et al.  CD40L-Containing Virus-Like Particle as a Candidate HIV-1 Vaccine Targeting Dendritic Cells , 2011, Journal of acquired immune deficiency syndromes.

[24]  Hee-Soo Lee,et al.  Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig , 2011, Virology Journal.

[25]  C. Basler,et al.  Vaccine Potential of Nipah Virus-Like Particles , 2011, PloS one.

[26]  M. Amacker,et al.  Influenza virosomes as a vaccine adjuvant and carrier system , 2011, Expert review of vaccines.

[27]  S. Hassan,et al.  Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines , 2011, Transgenic Research.

[28]  R. Sinden,et al.  Correction: Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial , 2011, PLoS ONE.

[29]  L. Lopalco,et al.  Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. , 2011, Immunity.

[30]  Min-Chul Kim,et al.  Influenza Virus-Like Particles Containing M2 Induce Broadly Cross Protective Immunity , 2011, PloS one.

[31]  Li Guo,et al.  Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice , 2011, Virology Journal.

[32]  John A. Robinson,et al.  Engineered Synthetic Virus‐Like Particles and Their Use in Vaccine Delivery , 2011, Chembiochem : a European journal of chemical biology.

[33]  R. Compans,et al.  Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus , 2010, Proceedings of the National Academy of Sciences.

[34]  Brian J. Ward,et al.  Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza , 2010, PloS one.

[35]  Adam Zlotnick,et al.  Virus assembly, allostery and antivirals , 2010, Trends in Microbiology.

[36]  Suh-Chin Wu,et al.  Construction and Characterization of Insect Cell-Derived Influenza VLP: Cell Binding, Fusion, and EGFP Incorporation , 2010, Journal of biomedicine & biotechnology.

[37]  S. El-Kamary,et al.  Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. , 2010, The Journal of infectious diseases.

[38]  R. Compans,et al.  Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic Protection , 2010, PloS one.

[39]  E. Rybicki,et al.  HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice , 2010, Journal of immune based therapies and vaccines.

[40]  D. Boscia,et al.  Cucumber mosaic virus as the expression system for a potential vaccine against Alzheimer's disease. , 2010, Journal of virological methods.

[41]  E. Kurt-Jones,et al.  Assembly and Immunological Properties of Newcastle Disease Virus-Like Particles Containing the Respiratory Syncytial Virus F and G Proteins , 2010, Journal of Virology.

[42]  A. Middelberg,et al.  Microbial production of virus-like particle vaccine protein at gram-per-litre levels. , 2010, Journal of biotechnology.

[43]  C. Davis,et al.  Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. , 2010, Virology.

[44]  T. Morrison.  Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens. , 2010, Future virology.

[45]  R. Compans,et al.  Changes in Human Langerhans Cells Following Intradermal Injection of Influenza Virus-Like Particle Vaccines , 2010, PloS one.

[46]  J. Wilschut,et al.  Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. , 2010, Vaccine.

[47]  P. Tiollais,et al.  Hepatitis B vaccines: protective efficacy and therapeutic potential. , 2010, Pathologie-biologie.

[48]  F. Buonaguro,et al.  Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches , 2010, Expert review of vaccines.

[49]  T. Tumpey,et al.  Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. , 2010, Vaccine.

[50]  F. Liu,et al.  Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice. , 2010, Vaccine.

[51]  L. Vézina,et al.  The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. , 2010, Plant biotechnology journal.

[52]  Jiang Li,et al.  Development of Tobacco necrosis virus A as a vector for efficient and stable expression of FMDV VP1 peptides. , 2010, Plant biotechnology journal.

[53]  D. Boscia,et al.  In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine. , 2010, Journal of virological methods.

[54]  P. Pumpens,et al.  Construction and Immunological Evaluation of Multivalent Hepatitis B Virus (HBV) Core Virus-Like Particles Carrying HBV and HCV Epitopes , 2010, Clinical and Vaccine Immunology.

[55]  A. Tissot,et al.  Versatile Virus-Like Particle Carrier for Epitope Based Vaccines , 2010, PloS one.

[56]  C. Chou,et al.  Mammalian Expression of Virus-Like Particles for Advanced Mimicry of Authentic Influenza Virus , 2010, PloS one.

[57]  Wei-Kung Wang,et al.  The Length of and Nonhydrophobic Residues in the Transmembrane Domain of Dengue Virus Envelope Protein Are Critical for Its Retention and Assembly in the Endoplasmic Reticulum , 2010, Journal of Virology.

[58]  Surbhi Jain,et al.  Assembly and Biological and Immunological Properties of Newcastle Disease Virus-Like Particles , 2010, Journal of Virology.

[59]  Chin-Tien Wang,et al.  Self-assembly of Severe Acute Respiratory Syndrome Coronavirus Membrane Protein , 2010, The Journal of Biological Chemistry.

[60]  R. Compans,et al.  Virus-Like Particle Vaccine Protects against 2009 H1N1 Pandemic Influenza Virus in Mice , 2010, PloS one.

[61]  H. Pehamberger,et al.  A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study , 2010, Breast Cancer Research and Treatment.

[62]  D. Fang,et al.  Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties , 2010, Virus Genes.

[63]  S. Higgs,et al.  A VLP vaccine for epidemic Chikungunya virus protects non-human primates against infection , 2010, Nature Medicine.

[64]  B. Ferko,et al.  Swine‐origin pandemic H1N1 influenza virus‐like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice , 2010, Biotechnology journal.

[65]  Yuliang Liu,et al.  Conserved Motifs within Ebola and Marburg Virus VP40 Proteins Are Important for Stability, Localization, and Subsequent Budding of Virus-Like Particles , 2009, Journal of Virology.

[66]  Ueli Aebi,et al.  A Nonadjuvanted Polypeptide Nanoparticle Vaccine Confers Long-Lasting Protection against Rodent Malaria1 , 2009, The Journal of Immunology.

[67]  M. Schleiss,et al.  Pandemic Influenza A (H1N1) , 2009, Pediatric Research.

[68]  A. Fraire,et al.  Newcastle Disease Virus-Like Particles Containing Respiratory Syncytial Virus G Protein Induced Protection in BALB/c Mice, with No Evidence of Immunopathology , 2009, Journal of Virology.

[69]  M. Amacker,et al.  Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells. , 2009, Vaccine.

[70]  D. Bracewell,et al.  Exploiting the intracellular compartmentalization characteristics of the S. cerevisiae host cell for enhancing primary purification of lipid‐envelope virus‐like particles , 2009, Biotechnology progress.

[71]  W. Fiers,et al.  M2e-based universal influenza A vaccine. , 2009, Vaccine.

[72]  R. Garcea,et al.  Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris , 2009, Archives of Virology.

[73]  R. Mukhopadhyaya,et al.  Production of immunogenic human papillomavirus-16 major capsid protein derived virus like particles. , 2009, The Indian journal of medical research.

[74]  C. Lico,et al.  Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. , 2009, Vaccine.

[75]  C. Herzog,et al.  Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. , 2009, Vaccine.

[76]  B. Winblad,et al.  Results of the first-in-man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients , 2009, Alzheimer's & Dementia.

[77]  B. Hjelm,et al.  A DNA replicon system for rapid high‐level production of virus‐like particles in plants , 2009, Biotechnology and bioengineering.

[78]  E. Rybicki,et al.  Optimization of chimeric HIV‐1 virus‐like particle production in a baculovirus‐insect cell expression system , 2009, Biotechnology progress.

[79]  T. Wisniewski,et al.  Immunotherapy targeting abnormal protein conformation , 2009, Alzheimer's & Dementia.

[80]  T. Ross,et al.  A Trivalent Virus-Like Particle Vaccine Elicits Protective Immune Responses against Seasonal Influenza Strains in Mice and Ferrets , 2009, PloS one.

[81]  J. Segalés,et al.  One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model. , 2009, Vaccine.

[82]  S. Zhang,et al.  Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells. , 2009, Molecular immunology.

[83]  Jean Cohen,et al.  Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. , 2009, Vaccine.

[84]  A. Schmitt,et al.  Mumps Virus Matrix, Fusion, and Nucleocapsid Proteins Cooperate for Efficient Production of Virus-Like Particles , 2009, Journal of Virology.

[85]  J. Haynes.  Influenza virus-like particle vaccines , 2009, Expert review of vaccines.

[86]  C. Russell,et al.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. , 2009, Vaccine.

[87]  C. Davis,et al.  Induction of Long-Term Protective Immune Responses by Influenza H5N1 Virus-Like Particles , 2009, PloS one.

[88]  F. Buonaguro,et al.  High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts , 2009, Planta.

[89]  M. Nuzzaci,et al.  Structural and biological properties of Cucumber mosaic virus particles carrying hepatitis C virus-derived epitopes. , 2009, Journal of virological methods.

[90]  Thomas R Kreil,et al.  Emerging trends in plasma‐free manufacturing of recombinant protein therapeutics expressed in mammalian cells , 2009, Biotechnology journal.

[91]  J. Bigger,et al.  Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. , 2009, Vaccine.

[92]  S. Sylvan,et al.  PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac™ vaccine and their relation to the antibody response to hepatitis B surface antigen , 2009, Virology Journal.

[93]  R. Compans,et al.  Protection against lethal challenge by Ebola virus-like particles produced in insect cells. , 2009, Virology.

[94]  R. Hodges,et al.  Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine , 2008, Chemical biology & drug design.

[95]  Brian J Ward,et al.  Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. , 2008, Plant biotechnology journal.

[96]  J. Treanor,et al.  FluBlok, a recombinant hemagglutinin influenza vaccine , 2008, Influenza and other respiratory viruses.

[97]  V. Mett,et al.  Plants as biofactories. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[98]  T. Tumpey,et al.  H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. , 2008, Vaccine.

[99]  V. Yusibov,et al.  Recent progress in the development of plant derived vaccines , 2008, Expert review of vaccines.

[100]  R. Compans,et al.  Incorporation of Membrane-Anchored Flagellin into Influenza Virus-Like Particles Enhances the Breadth of Immune Responses , 2008, Journal of Virology.

[101]  C. Gray,et al.  HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. , 2008, The Journal of general virology.

[102]  A. Sirko,et al.  Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4. , 2008, Hybridoma.

[103]  S. Wain-Hobson,et al.  Immunogenicity and tolerance following HIV-1/HBV plant-based oral vaccine administration. , 2008, Vaccine.

[104]  P. Roy,et al.  Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins , 2008, Virology Journal.

[105]  Zhènglì Shí,et al.  Virus-Like Particles of SARS-Like Coronavirus Formed by Membrane Proteins from Different Origins Demonstrate Stimulating Activity in Human Dendritic Cells , 2008, PloS one.

[106]  J. Cornuz,et al.  A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial , 2008, PloS one.

[107]  S. Krishnamurthy,et al.  Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. , 2008, Vaccine.

[108]  E. Rybicki,et al.  Expression of HIV-1 antigens in plants as potential subunit vaccines , 2008, BMC biotechnology.

[109]  R. Compans,et al.  A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. , 2008, Vaccine.

[110]  G. Chang,et al.  A strong endoplasmic reticulum retention signal in the stem-anchor region of envelope glycoprotein of dengue virus type 2 affects the production of virus-like particles. , 2008, Virology.

[111]  L. Nemchinov,et al.  Improvement of PVX/CMV CP expression tool for display of short foreign antigens. , 2008, Protein expression and purification.

[112]  H. Yoshikawa,et al.  Modification of human papillomavirus‐like particle vaccine by insertion of the cross‐reactive L2‐epitopes , 2008, Journal of medical virology.

[113]  E. Rybicki,et al.  Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. , 2008, Virus research.

[114]  Hong-Jin Kim,et al.  Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. , 2008, Protein expression and purification.

[115]  B. Hjelm,et al.  An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. , 2008, Vaccine.

[116]  Sue-N. Park,et al.  Expression and purification of human papillomavirus 18 L1 virus-like particle from Saccharomyces cerevisiae , 2008, Archives of pharmacal research.

[117]  H. Volk,et al.  Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study , 2008, The Lancet.

[118]  T. Tumpey,et al.  Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle , 2008, PloS one.

[119]  P. Roy,et al.  Virus‑like particles as a vaccine delivery system: Myths and facts , 2008, Human vaccines.

[120]  Martin Müller,et al.  Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. , 2007, Virology.

[121]  K. Boyd,et al.  Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. , 2007, Vaccine.

[122]  M. Fay,et al.  A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. , 2007, The Journal of infectious diseases.

[123]  P. Hillemanns,et al.  Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3) , 2007, International journal of cancer.

[124]  Markus S. Mueller,et al.  A Virosomal Malaria Peptide Vaccine Elicits a Long-Lasting Sporozoite-Inhibitory Antibody Response in a Phase 1a Clinical Trial , 2007, PloS one.

[125]  J. Paavonen.  Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[126]  Jianjun Chen,et al.  Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice , 2007, Immunology.

[127]  S. Wain-Hobson,et al.  Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine. , 2007, Vaccine.

[128]  W. Kalina,et al.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. , 2007, The Journal of infectious diseases.

[129]  J. Hartley,et al.  Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. , 2007, The Journal of infectious diseases.

[130]  Y. Kawaoka,et al.  Mapping of a region of Ebola virus VP40 that is important in the production of virus-like particles. , 2007, The Journal of infectious diseases.

[131]  D. Leclerc,et al.  Novel Plant Virus-Based Vaccine Induces Protective Cytotoxic T-Lymphocyte-Mediated Antiviral Immunity through Dendritic Cell Maturation , 2007, Journal of Virology.

[132]  A. Chaturvedi,et al.  Hematologic and biochemical changes associated with human T lymphotropic virus type 1 infection in Jamaica: a report from the population-based blood donors study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[133]  A. Cupo,et al.  A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). , 2007, Viral immunology.

[134]  R. Johnston,et al.  Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats , 2007, Journal of Virology.

[135]  M. Amacker,et al.  A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. , 2007, Vaccine.

[136]  M. Tanner,et al.  A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers , 2007, PloS one.

[137]  S. Liang,et al.  Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes , 2007, BMC biotechnology.

[138]  N. Christensen,et al.  Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum , 2007, BMC biotechnology.

[139]  D. Lowy,et al.  Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. , 2007, JAMA.

[140]  D. Leclerc,et al.  Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. , 2007, Virology.

[141]  K. Ault.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials , 2007, The Lancet.

[142]  B. Chackerian,et al.  Virus-like particles: flexible platforms for vaccine development , 2007, Expert review of vaccines.

[143]  T. Tumpey,et al.  Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. , 2007, Vaccine.

[144]  C. Leclerc,et al.  Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN , 2007, The Journal of Immunology.

[145]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[146]  T. Ross,et al.  Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. , 2007, Vaccine.

[147]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[148]  R. Lamb,et al.  Influenza Virus Hemagglutinin and Neuraminidase, but Not the Matrix Protein, Are Required for Assembly and Budding of Plasmid-Derived Virus-Like Particles , 2007, Journal of Virology.

[149]  T. Breinig,et al.  Exploiting the Yeast L-A Viral Capsid for the In Vivo Assembly of Chimeric VLPs as Platform in Vaccine Development and Foreign Protein Expression , 2007, PloS one.

[150]  L. Rasochova,et al.  Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis. , 2007, Journal of virological methods.

[151]  Jun Chang,et al.  Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection , 2007, Journal of Virology.

[152]  R. Roden,et al.  A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. , 2007, Vaccine.

[153]  L. Rasochova,et al.  Expression and self-assembly of cowpea chlorotic mottle virus-like particles in Pseudomonas fluorescens. , 2007, Journal of biotechnology.

[154]  R. Compans,et al.  Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus , 2007, Journal of Virology.

[155]  H. Volk,et al.  A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity , 2007, Journal of hypertension.

[156]  M. Xia,et al.  Norovirus capsid protein expressed in yeast forms virus‐like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts , 2007, Journal of medical virology.

[157]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[158]  R. Compans,et al.  Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- MacrophageColony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles , 2006, Journal of Virology.

[159]  F. Buonaguro,et al.  Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses , 2006, Journal of Virology.

[160]  N. Young,et al.  Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus. , 2006, The Journal of infectious diseases.

[161]  M. Peeples,et al.  Requirements for the Assembly and Release of Newcastle Disease Virus-Like Particles , 2006, Journal of Virology.

[162]  V. Volchkov,et al.  Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses , 2006, Virology Journal.

[163]  Zhong Huang,et al.  Virus-like particles production in green plants. , 2006, Methods.

[164]  R. Ulrich,et al.  Generation of virus-like particles consisting of the major capsid protein VP1 of goose hemorrhagic polyomavirus and their application in serological tests. , 2006, Virus research.

[165]  E. Rybicki,et al.  Transient expression of Human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. , 2006, Virus research.

[166]  David A. Anderson,et al.  Virus-like particles: Passport to immune recognition , 2006, Methods.

[167]  B. Pulendran,et al.  Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. , 2006, Virology.

[168]  J. Bi,et al.  Molecular characterization of recombinant Hepatitis B surface antigen from Chinese hamster ovary and Hansenula polymorpha cells by high-performance size exclusion chromatography and multi-angle laser light scattering. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[169]  A. M. Hutson,et al.  Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. , 2006, Plant biotechnology journal.

[170]  M. Carrondo,et al.  A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. , 2006, Vaccine.

[171]  S. Shchelkunov,et al.  Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses , 2006, Biotechnology Letters.

[172]  R. N. Harty,et al.  Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology , 2006, Virology Journal.

[173]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[174]  P. Pothier,et al.  Intrarectal Immunization with Rotavirus 2/6 Virus-Like Particles Induces an Antirotavirus Immune Response Localized in the Intestinal Mucosa and Protects against Rotavirus Infection in Mice , 2006, Journal of Virology.

[175]  Zhong Huang,et al.  Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. , 2006, Vaccine.

[176]  T. Mor,et al.  Production of rotavirus-like particles in tomato (Lycopersicon esculentum L.) fruit by expression of capsid proteins VP2 and VP6 and immunological studies. , 2006, Viral immunology.

[177]  R. Hammond,et al.  Epitope presentation system based on cucumber mosaic virus coat protein expressed from a potato virus X-based vector , 2006, Archives of Virology.

[178]  M. Ho,et al.  Expression, purification and characterization of enterovirus-71 virus-like particles. , 2006, World journal of gastroenterology.

[179]  S. Gagné,et al.  Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein , 2006, The FEBS journal.

[180]  G. Pérez-Martínez,et al.  Production of Human Papillomavirus Type 16 L1 Virus-Like Particles by Recombinant Lactobacillus casei Cells , 2006, Applied and Environmental Microbiology.

[181]  T. Tumpey,et al.  Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. , 2005, Vaccine.

[182]  H. Koprowski,et al.  Advances in alfalfa mosaic virus-mediated expression of anthrax antigen in planta. , 2005, Biochemical and biophysical research communications.

[183]  Paula M Alves,et al.  Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production. , 2005, Journal of biotechnology.

[184]  J. Oem,et al.  Noninfectious Virus-Like Particle Antigen for Detection of Swine Vesicular Disease Virus Antibodies in Pigs by Enzyme-Linked Immunosorbent Assay , 2005, Clinical Diagnostic Laboratory Immunology.

[185]  D. Swenson,et al.  Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection1 , 2005, The Journal of Immunology.

[186]  G. Jennings,et al.  A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity , 2005, European journal of immunology.

[187]  P. Kremsner,et al.  Safety and Enhanced Immunogenicity of a Hepatitis B Core Particle Plasmodium falciparum Malaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial , 2005, Infection and Immunity.

[188]  M. Amacker,et al.  Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. , 2005, International immunology.

[189]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[190]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[191]  M. Aman,et al.  Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. , 2005, Vaccine.

[192]  S. Plotkin,et al.  Vaccines: past, present and future , 2005, Nature Medicine.

[193]  A. Cupo,et al.  Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. , 2005, Viral immunology.

[194]  D. Mann,et al.  Peptide-based candidate vaccine against respiratory syncytial virus. , 2005, Vaccine.

[195]  G. Chang,et al.  Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. , 2005, Virology.

[196]  Zhong Huang,et al.  Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. , 2005, Vaccine.

[197]  N. Natarajan,et al.  Immunogenicity in humans of an edible vaccine for hepatitis B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[198]  R. Wagner,et al.  Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. , 2005, Molecular immunology.

[199]  D. Eckery,et al.  Oral and intraperitoneal immunization with rotavirus 2/6 virus-like particles stimulates a systemic and mucosal immune response in mice , 2005, Archives of Virology.

[200]  S. Becker,et al.  Multivesicular Bodies as a Platform for Formation of the Marburg Virus Envelope , 2004, Journal of Virology.

[201]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[202]  Ashley J. Birkett,et al.  Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes , 2004, Infection and Immunity.

[203]  P. Roy,et al.  Efficient assembly and release of SARS coronavirus‐like particles by a heterologous expression system , 2004, FEBS Letters.

[204]  M. Aman,et al.  Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. , 2004, Vaccine.

[205]  G. Ruthel,et al.  Ebola and Marburg virus-like particles activate human myeloid dendritic cells. , 2004, Virology.

[206]  Wei Zhao,et al.  Expression and self-assembly of HCV structural proteins into virus-like particles and their immunogenicity. , 2004, Chinese medical journal.

[207]  H. Young,et al.  Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection , 2004, The Journal of experimental medicine.

[208]  Ziying Han,et al.  Contribution of Ebola Virus Glycoprotein, Nucleoprotein, and VP24 to Budding of VP40 Virus-Like Particles , 2004, Journal of Virology.

[209]  Zongyi Hu,et al.  Immunization with Hepatitis C Virus-Like Particles Induces Humoral and Cellular Immune Responses in Nonhuman Primates , 2004, Journal of Virology.

[210]  K. Boyd,et al.  Recombinant Sendai Virus Expressing the G Glycoprotein of Respiratory Syncytial Virus (RSV) Elicits Immune Protection against RSV , 2004, Journal of Virology.

[211]  C. Y. Liu,et al.  Assembly of human severe acute respiratory syndrome coronavirus-like particles , 2004, Biochemical and Biophysical Research Communications.

[212]  L. Saif,et al.  Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus‐like particle (VLP) boosting with ISCOM , 2004, Clinical and experimental immunology.

[213]  C. Williamson,et al.  Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. , 2004, The Journal of general virology.

[214]  T. Miyamura,et al.  Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. , 2004, Vaccine.

[215]  B. Griffin,et al.  Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles. , 2004, Vaccine.

[216]  M. Mohamadzadeh,et al.  Ebola virus-like particles protect from lethal Ebola virus infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[217]  B. Autran,et al.  Yeast-Derived Human Immunodeficiency Virus Type 1 p55gag Virus-Like Particles Activate Dendritic Cells (DCs) and Induce Perforin Expression in Gag-Specific CD8+ T Cells by Cross-Presentation of DCs , 2003, Journal of Virology.

[218]  Zhengkai Xu,et al.  Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. , 2003, Vaccine.

[219]  M. Estes,et al.  Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. , 2003, Vaccine.

[220]  M. Shuler,et al.  Structural characterization of plant-derived hepatitis B surface antigen employed in oral immunization studies. , 2003, Vaccine.

[221]  R. Rose,et al.  Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi , 2003, Archives of Virology.

[222]  L. Willmitzer,et al.  Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants , 2003, Journal of Virology.

[223]  G. Lomonossoff,et al.  Expression & immunogenicity of malaria merozoite peptides displayed on the small coat protein of chimaeric cowpea mosaic virus. , 2003, The Indian journal of medical research.

[224]  C. Tacket,et al.  Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. , 2003, Clinical immunology.

[225]  R. Rose,et al.  Oral Immunogenicity of Human Papillomavirus-Like Particles Expressed in Potato , 2003, Journal of Virology.

[226]  J. Castón,et al.  Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines. , 2003, Vaccine.

[227]  D. Wakelin,et al.  Effect of priming/booster immunisation protocols on immune response to canine parvovirus peptide induced by vaccination with a chimaeric plant virus construct. , 2003, Vaccine.

[228]  I. V. D. van der Linden,et al.  Virological kinetics and immunological responses to a porcine reproductive and respiratory syndrome virus infection of pigs at different ages. , 2003, Vaccine.

[229]  T. Liang,et al.  Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[230]  J. Roehrig,et al.  Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. , 2003, Virology.

[231]  A. Zvirbliene,et al.  Generation of Recombinant Virus-Like Particles of Human and Non-Human Polyomaviruses in Yeast Saccharomyces cerevisiae , 2003, Intervirology.

[232]  A. Schmidt,et al.  A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of the Plasmodium falciparum Circumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts , 2002, Infection and Immunity.

[233]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[234]  R. Glück,et al.  Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. , 2002, Vaccine.

[235]  H. Koprowski,et al.  Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. , 2002, Vaccine.

[236]  D. Wakelin,et al.  Characterization of the immune response to canine parvovirus induced by vaccination with chimaeric plant viruses. , 2002, Vaccine.

[237]  Y. Morikawa,et al.  HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[238]  M. Carrondo,et al.  Large scale production and downstream processing of a recombinant porcine parvovirus vaccine , 2002, Applied Microbiology and Biotechnology.

[239]  P. McMinn,et al.  Murray Valley encephalitis virus recombinant subviral particles protect mice from lethal challenge with virulent wild-type virus , 2002, Archives of Virology.

[240]  Joy A. Cavagnaro,et al.  Preclinical safety evaluation of biotechnology-derived pharmaceuticals , 2002, Nature Reviews Drug Discovery.

[241]  Emiko Suzuki,et al.  Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP , 2002, Journal of Virology.

[242]  P. McMinn.  An overview of the evolution of enterovirus 71 and its clinical and public health significance. , 2002, FEMS microbiology reviews.

[243]  Jinhyung Kim,et al.  Characterization of the recombinant proteins of porcine circovirus type2 field isolate expressed in the baculovirus system. , 2002, Journal of veterinary science.

[244]  M. Sällberg,et al.  Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. , 2001, Vaccine.

[245]  GWONG‐JEN J. Chang,et al.  Flavivirus DNA Vaccines , 2001 .

[246]  E. Kohli,et al.  Rotavirus 2/6 Virus-Like Particles Administered Intranasally in Mice, with or without the Mucosal Adjuvants Cholera Toxin and Escherichia coli Heat-Labile Toxin, Induce a Th1/Th2-Like Immune Response , 2001, Journal of Virology.

[247]  M. Estes,et al.  Recombinant Norwalk Virus-Like Particles Administered Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune Responses , 2001, Journal of Virology.

[248]  W. Bentley,et al.  Effect of MOI ratio on the composition and yield of chimeric infectious bursal disease virus-like particles by baculovirus co-infection: deterministic predictions and experimental results. , 2001, Biotechnology and bioengineering.

[249]  D. Cooper,et al.  Therapeutic vaccination (p24‐VLP) of patients with advanced HIV‐1 infection in the pre‐HAART era does not alter CD4 cell decline , 2001, HIV medicine.

[250]  F. Belardelli,et al.  Chimeric Plant Virus Particles as Immunogens for Inducing Murine and Human Immune Responses against Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[251]  A. Musacchio,et al.  Characterization of the HCV core virus-like particles produced in the methylotrophic yeast Pichia pastoris. , 2001, Biochemical and biophysical research communications.

[252]  C. Arntzen,et al.  Oral immunization with hepatitis B surface antigen expressed in transgenic plants , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[253]  T. Liang,et al.  Hepatitis C virus–like particles induce virus‐specific humoral and cellular immune responses in mice , 2001, Hepatology.

[254]  J. Galarza,et al.  Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural Proteins , 2001, Journal of Virology.

[255]  R. Boshuizen,et al.  Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. , 2001, Vaccine.

[256]  K. Jansen,et al.  Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. , 2001, Vaccine.

[257]  S. Swaminathan,et al.  Expression of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter. , 2001, Journal of biotechnology.

[258]  G. Neumann,et al.  Ebola Virus VP40-Induced Particle Formation and Association with the Lipid Bilayer , 2001, Journal of Virology.

[259]  Y. Li,et al.  Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. , 2001, Vaccine.

[260]  T. Miyamura,et al.  Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. , 2001, Vaccine.

[261]  Denise A. Martin,et al.  West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays , 2001, Journal of Virology.

[262]  L. Lorenzo,et al.  Assembly of truncated HCV core antigen into virus-like particles in Escherichia coli. , 2001, Biochemical and biophysical research communications.

[263]  K. Kataoka,et al.  Roles of Disulfide Linkage and Calcium Ion-Mediated Interactions in Assembly and Disassembly of Virus-Like Particles Composed of Simian Virus 40 VP1 Capsid Protein , 2001, Journal of Virology.

[264]  A. Oppenheim,et al.  Production and purification of SV40 major capsid protein (VP1) in Escherichia coli strains deficient for the GroELS chaperone machine. , 2000, Journal of biotechnology.

[265]  P. Gómez-Puertas,et al.  Influenza Virus Matrix Protein Is the Major Driving Force in Virus Budding , 2000, Journal of Virology.

[266]  H. Bélanger,et al.  Human respiratory syncytial virus vaccine antigen produced in plants , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[267]  C. Arntzen,et al.  Production of hepatitis B surface antigen in transgenic plants for oral immunization , 2000, Nature Biotechnology.

[268]  J. Sirard,et al.  Nasal Immunization of Mice with Virus-Like Particles Protects Offspring against Rotavirus Diarrhea , 2000, Journal of Virology.

[269]  M. Estes,et al.  Intranasal Administration of 2/6-Rotavirus-Like Particles with Mutant Escherichia coli Heat-Labile Toxin (LT-R192G) Induces Antibody-Secreting Cell Responses but Not Protective Immunity in Gnotobiotic Pigs , 2000, Journal of Virology.

[270]  J. Heitman.  Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 2000, Mycopathologia.

[271]  M. Levine,et al.  Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. , 2000, The Journal of infectious diseases.

[272]  H. Field,et al.  Nipah virus: a recently emergent deadly paramyxovirus. , 2000, Science.

[273]  G. Chang,et al.  A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice , 2000, Journal of Virology.

[274]  B. Speelman,et al.  Theoretical studies of viral capsid proteins. , 2000, Current opinion in structural biology.

[275]  John E. Johnson,et al.  Influence of three‐dimensional structure on the immunogenicity of a peptide expressed on the surface of a plant virus , 2000, Journal of molecular recognition : JMR.

[276]  E. Hardy,et al.  Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. , 2000, Journal of biotechnology.

[277]  R. Compans,et al.  Production and characterization of simian--human immunodeficiency virus-like particles. , 2000, AIDS research and human retroviruses.

[278]  R. Wagner,et al.  Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. , 2000, AIDS research and human retroviruses.

[279]  C. Carrillo,et al.  Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1. , 1999, Virology.

[280]  P. Coursaget,et al.  Nasal Immunization of Mice with Human Papillomavirus Type 16 (HPV-16) Virus-Like Particles or with the HPV-16 L1 Gene Elicits Specific Cytotoxic T Lymphocytes in Vaginal Draining Lymph Nodes , 1999, Journal of Virology.

[281]  Adeeba Kamarulzaman,et al.  Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia , 1999, The Lancet.

[282]  M. Figlerowicz,et al.  A plant‐derived edible vaccine against hepatitis B virus , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[283]  F. Notka,et al.  Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies. , 1999, Vaccine.

[284]  W. Hamilton,et al.  A chimaeric plant virus vaccine protects mice against a bacterial infection. , 1999, Microbiology.

[285]  D. Graham,et al.  Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. , 1999, Gastroenterology.

[286]  A. Benner,et al.  Immune response to human papillomavirus 16 L1E7 chimeric virus‐like particles: Induction of cytotoxic T cells and specific tumor protection , 1999, International journal of cancer.

[287]  H. Petry,et al.  Molecular Cloning and Expression of Major Structural Protein VP1 of the Human Polyomavirus JC Virus: Formation of Virus-Like Particles Useful for Immunological and Therapeutic Studies , 1999, Journal of Virology.

[288]  W. Hamilton,et al.  Immunogenicity of peptides derived from a fibronectin-binding protein of S. aureus expressed on two different plant viruses. , 1999, Vaccine.

[289]  M. Noteborn,et al.  Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specific neutralizing epitope. , 1998, The Journal of general virology.

[290]  B. Corsaro,et al.  Synthesis of rotavirus-like particles in insect cells: comparative and quantitative analysis. , 1998, Biotechnology and bioengineering.

[291]  N. Dimmock,et al.  Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. , 1998, Journal of immunological methods.

[292]  D. Wong,et al.  Hepatitis C Virus Structural Proteins Assemble into Viruslike Particles in Insect Cells , 1998, Journal of Virology.

[293]  J. Albar,et al.  Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles. , 1998, The Journal of general virology.

[294]  M. Stanley,et al.  Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro. , 1998, Virology.

[295]  Y. Okada,et al.  Application of the Human Hepatitis B Virus Core Antigen from Transgenic Tobacco Plants for Serological Diagnosis , 1998, Vox Sanguinis.

[296]  M. Estes,et al.  Rotavirus 2/6 Viruslike Particles Administered Intranasally with Cholera Toxin, Escherichia coli Heat-Labile Toxin (LT), and LT-R192G Induce Protection from Rotavirus Challenge , 1998, Journal of Virology.

[297]  R. Ward,et al.  Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. , 1998, Virology.

[298]  Z. Fu,et al.  Immunization against rabies with plant-derived antigen. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[299]  D. Lowy,et al.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[300]  M. Estes,et al.  Oral Immunization with Recombinant Norwalk Virus-Like Particles Induces a Systemic and Mucosal Immune Response in Mice , 1998, Journal of Virology.

[301]  K. Jansen,et al.  Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. , 1997, The Journal of infectious diseases.

[302]  J. Weber,et al.  A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. , 1997, The Journal of infection.

[303]  T. Miyamura,et al.  Expression and self-assembly of empty virus-like particles of hepatitis E virus , 1997, Journal of virology.

[304]  R. Wagner,et al.  Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. , 1997, Virology.

[305]  B L Trus,et al.  The making and breaking of symmetry in virus capsid assembly: glimpses of capsid biology from cryoelectron microscopy , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[306]  S. Li,et al.  Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. , 1997, The Journal of general virology.

[307]  R. Dagan,et al.  Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. , 1997, The Pediatric infectious disease journal.

[308]  D. Weiner,et al.  Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[309]  Y. Barenholz,et al.  Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. , 1997, Vaccine.

[310]  R. Boshuizen,et al.  Plant–derived vaccine protects target animals against a viral disease , 1997, Nature Biotechnology.

[311]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[312]  J. Peponis.  Formulation , 1997, Encyclopedic Dictionary of Archaeology.

[313]  R. Wagner,et al.  Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. , 1996, Virology.

[314]  M. Estes,et al.  Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[315]  H. Handa,et al.  Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. , 1996, Biochimica et biophysica acta.

[316]  M. Estes,et al.  Characterization and replicase activity of double-layered and single-layered rotavirus-like particles expressed from baculovirus recombinants , 1996, Journal of virology.

[317]  R. Compans,et al.  Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. , 1995, Virology.

[318]  M. Betenbaugh,et al.  Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. , 1995, Virus research.

[319]  J. Smilack.  Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 1995 .

[320]  P. Lyons,et al.  Immunogenicity of transgenic plant-derived hepatitis B surface antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[321]  G. Lomonossoff,et al.  Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. , 1995, AIDS research and human retroviruses.

[322]  I. Rodrı́guez-Crespo,et al.  Antigenicity of hepatitis B surface antigen proteins reconstituted with phospholipids. , 1995, Biochimica et biophysica acta.

[323]  T. Sasagawa,et al.  Synthesis and assembly of virus-like particles of human papillomaviruses type 6and Type 16 in fission yeast Schizosaccharomyces pombe , 1995 .

[324]  D. Rasschaert,et al.  Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection , 1994, Journal of virology.

[325]  N. Christensen,et al.  Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. , 1994, The Journal of general virology.

[326]  M. Estes,et al.  Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells , 1994, Journal of virology.

[327]  John E. Johnson,et al.  Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. , 1994, Virology.

[328]  I. Rodrı́guez-Crespo,et al.  Reconstitution of hepatitis B surface antigen proteins into phospholipid vesicles. , 1994, Biochimica et biophysica acta.

[329]  F. Rixon,et al.  Assembly of herpes simplex virus type 1 capsids using a panel of recombinant baculoviruses. , 1994, The Journal of general virology.

[330]  P. Francioli,et al.  Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[331]  D. Lowy,et al.  Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles , 1993, Journal of virology.

[332]  V. Suvatte,et al.  Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults. , 1993, Asian Pacific journal of allergy and immunology.

[333]  P. Roy,et al.  Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. , 1993, Nucleic acids research.

[334]  E. Snezhkov,et al.  Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. , 1993, Virology.

[335]  D. Lowy,et al.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[336]  D. M. Lam,et al.  Expression of hepatitis B surface antigen in transgenic plants. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[337]  D. Graham,et al.  Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein , 1992, Journal of virology.

[338]  E. Cortés,et al.  Recombinant vaccine for canine parvovirus in dogs , 1992, Journal of virology.

[339]  L. Babiuk,et al.  Assembly of double-shelled rotaviruslike particles by simultaneous expression of recombinant VP6 and VP7 proteins , 1991, Journal of virology.

[340]  Simon C Watkins,et al.  Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1 , 1991, Journal of virology.

[341]  J Huchet,et al.  Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. , 1991, Vaccine.

[342]  S. Kajigaya,et al.  Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[343]  M. Estes,et al.  Expression of rotavirus VP2 produces empty corelike particles , 1991, Journal of virology.

[344]  J. Vlak,et al.  Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins , 1991, Journal of virology.

[345]  M. Gu,et al.  Growth rate control in fed-batch cultures of recombinant Saccharomyces cerevisiae producing hepatitis B surface antigen (HBsAg) , 1991, Applied Microbiology and Biotechnology.

[346]  E. Nagy,et al.  Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV. , 1991, The Journal of general virology.

[347]  P. Roy,et al.  Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins , 1990, Journal of virology.

[348]  P. Roy,et al.  Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV , 1990, Journal of virology.

[349]  J. González-Ros,et al.  Hepatitis B surface antigen. Role of lipids in maintaining the structural and antigenic properties of protein components. , 1990, The Biochemical journal.

[350]  E. Jacobs,et al.  Assembly and release of HIV-1 precursor Pr55 gag virus-like particles from recombinant baculovirus-infected insect cells , 1989, Cell.

[351]  R. Ellis,et al.  Plasma-derived and yeast-derived hepatitis B vaccines. , 1989, American journal of infection control.

[352]  I. Jones,et al.  The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system. , 1989, Virology.

[353]  D. Bishop,et al.  Co-expression of the hepatitis B surface and core antigens using baculovirus multiple expression vectors. , 1988, The Journal of general virology.

[354]  A. Dalgleish,et al.  Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. , 1988, Virology.

[355]  K. Murray.  Application of recombinant DNA techniques in the development of viral vaccines. , 1988, Vaccine.

[356]  A. Kingsman,et al.  The expression of hybrid HIV:Ty virus-like particles in yeast , 1987, Nature.

[357]  J. Cregg,et al.  High–Level Expression and Efficient Assembly of Hepatitis B Surface Antigen in the Methylotrophic Yeast, Pichia Pastoris , 1987, Bio/Technology.

[358]  A. Zuckerman,et al.  Hepatitis B surface antigen polypeptide micelles from antigen expressed in Saccharomyces cerevisiae. , 1986, Journal of virological methods.

[359]  G. Nakamura,et al.  Intracellular assembly and packaging of hepatitis B surface antigen particles occur in the endoplasmic reticulum , 1986, Journal of virology.

[360]  V. Lingappa,et al.  Hepatitis B surface antigen: an unusual secreted protein initially synthesized as a transmembrane polypeptide , 1986, Molecular and cellular biology.

[361]  T. Roberts,et al.  Polyoma virus major capsid protein, VP1. Purification after high level expression in Escherichia coli. , 1985, The Journal of biological chemistry.

[362]  P. Pontisso,et al.  Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[363]  G. Bitter,et al.  Expression of heterologous genes in Saccharomyces cerevisiae from vectors utilizing the glyceraldehyde-3-phosphate dehydrogenase gene promoter. , 1984, Gene.

[364]  M. Hilleman,et al.  Human hepatitis B vaccine from recombinant yeast , 1984, Nature.

[365]  J. V. Miller,et al.  Expression of hepatitis B virus surface antigen in yeast. , 1983, Nucleic acids research.

[366]  B D Hall,et al.  Synthesis and assembly of hepatitis B virus surface antigen particles in yeast , 1982, Nature.

[367]  J. González-Ros,et al.  Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins. , 1982, The Journal of biological chemistry.

[368]  C. Hall,et al.  Respiratory Syncytial Virus , 1983 .

[369]  A. J. Zuckerman,et al.  Hepatitis B polypeptide vaccine preparation in micelle form , 1981, Nature.

[370]  W. Robinson,et al.  The virus of hepatitis, type B. (Second of two parts). , 1976, The New England journal of medicine.

[371]  W. Robinson,et al.  The virus of hepatitis, type B. (Second of two parts). , 1976 .

[372]  T. Heath,et al.  FORMATION OF VIROSOMES FROM INFLUENZA SUBUNITS AND LIPOSOMES , 1975, The Lancet.

[373]  P. Rhodes.  Administration. , 1933, Teachers College Record: The Voice of Scholarship in Education.

[374]  J. Stockman.  First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children , 2013 .

[375]  R. VAN DEN HOVEN,et al.  Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses. , 2012, Equine veterinary journal.

[376]  Yang Yan.  Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants , 2011 .

[377]  E. Rybicki,et al.  High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. , 2010, Plant biotechnology journal.

[378]  Y. Qian,et al.  Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants , 2010, Science China Life Sciences.

[379]  B. Chackerian.  Virus-like particle based vaccines for Alzheimer disease. , 2010, Human vaccines.

[380]  P. Bovier.  Recent advances with a virosomal hepatitis A vaccine. , 2008, Expert opinion on biological therapy.

[381]  유재랑.  Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection , 2008 .

[382]  Sue-N. Park,et al.  Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae. , 2007, Journal of virological methods.

[383]  I. Tomlinson,et al.  Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. , 2007, The Journal of infectious diseases.

[384]  C. Tacket.  Plant-based vaccines against diarrheal diseases. , 2007, Transactions of the American Clinical and Climatological Association.

[385]  L. Shulman.  Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. , 2007, The Journal of infectious diseases.

[386]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[387]  K. Skryabin,et al.  The use of viral vectors to produce hepatitis B virus core particles in plants. , 2006, Journal of virological methods.

[388]  Gary Adam Zeitlin,et al.  Avian Influenza , 2005, Current infectious disease reports.

[389]  S. Lam.  Nipah virus--a potential agent of bioterrorism? , 2003, Antiviral research.

[390]  G. Kuno,et al.  Flavivirus DNA vaccines: current status and potential. , 2001, Annals of the New York Academy of Sciences.

[391]  M. Prevost,et al.  High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. , 2001, Antiviral research.

[392]  D. Shouval,et al.  Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. , 2001, Journal of hepatology.

[393]  D. Shouval,et al.  Rapid seroprotection against hepatitis B following the ® rst dose of a PreS 1 / PreS 2 / S vaccine , 2000 .

[394]  F. Kibenge,et al.  Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. , 1999, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

[395]  M. Wainberg,et al.  Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles , 1999, Biological chemistry.

[396]  J. Johnson,et al.  Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. , 1999, Microbiology.

[397]  Guez,et al.  Expression of ORF A 1 of infectious bursal disease virus results in the formation of virus-like particles , 1998 .

[398]  J. B. Bravo González,et al.  [Adverse reactions and immune response to Heberbiovac-HB vaccine administered to infants simultaneously with DPT and VA-MENGOC-BC]. , 1997, Revista cubana de medicina tropical.

[399]  M. González,et al.  Reacciones adversas y respuesta inmune de la vacuna Heberbiovac-HB aplicada a lactantes, simultáneamente con la DPT y la VA-MENGOC-BC , 1997 .

[400]  K. Jansen,et al.  Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae. , 1996, Gene.

[401]  J. Reimann,et al.  Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. , 1996, Intervirology.

[402]  W. Werz,et al.  Process scale considerations in evaluation studies and scale-up. , 1996, Developments in biological standardization.

[403]  J. Reimann,et al.  Virus-Like Particles Induce MHC Class I-Restricted T-Cell Responses , 1996 .

[404]  A. Kingsman,et al.  Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. , 1995, Vaccine.

[405]  T. Sasagawa,et al.  Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. , 1995, Virology.

[406]  M. Noteborn,et al.  Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus. , 1995, Vaccine.

[407]  M. Rosolowsky,et al.  Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. , 1995, Vaccine.

[408]  S. Hoffman,et al.  Malaria Epitopes Expressed on the surface of Recombinant Tobacco Mosaic Virus , 1995, Bio/Technology.

[409]  S. Alexandersen,et al.  Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink. , 1994, The Journal of general virology.

[410]  P. Roy,et al.  Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. , 1994, Vaccine.

[411]  P. Roy,et al.  Protective efficacy of virus-like particles for bluetongue disease. , 1992, Vaccine.

[412]  E. Cortés,et al.  Production of porcine parvovirus empty capsids with high immunogenic activity. , 1992, Vaccine.

[413]  J. Stéphenne.  Production in yeast versus mammalian cells of the first recombinant DNA human vaccine and its proved safety, efficacy, and economy: hepatitis B vaccine. , 1990, Advances in biotechnological processes.

[414]  E. Simoen,et al.  Immunological properties of recombinant HBsAg produced in yeast. , 1987, Postgraduate medical journal.

[415]  M. Crabeel,et al.  Expression of hepatitis B surface antigen in yeast. , 1983, Developments in biological standardization.

[416]  A. Helenius,et al.  Virus spike protein complexes and virosomes as effective subunit vaccines. , 1979, Advances in experimental medicine and biology.

[417]  Évin,et al.  A CONTROLLED TRIAL OF A HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE , 2022 .

[418]  R. Compans,et al.  Virus-Like Particle Vaccine Protects against 2009 H1N1 Pandemic Influenza Virus in Mice , 2010, PloS one.